Danielle M. Brander, MD

Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.

Danielle M. Brander, MD, remarks on the appropriateness for targeted therapy as a treatment option for a 73-year-old man with relapsed chronic lymphocytic leukemia.

Danielle M. Brander, MD, assistant professor of medicine at Duke University School of Medicine and member of the Duke Cancer Institute, discusses a major challenge in the field of chronic lymphocytic leukemia. She says the biggest challenge to overcome in the treatment of patients with CLL is navigating areas where research is not yet mature.